WXIBF:OTC-WuXi Biologics (Cayman) Inc (USD)

COMMON STOCK | | OTC

Last Closing Price

USD 13.56

Change

0.00 (0.00)%

Market Cap

USD 58.87B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

WuXi Biologics (Cayman) Inc., an investment holding company, operates as an open-access technology platform company that provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology; international sales contracting services; testing and development of testing technologies; provision of biologics clinical and manufacturing services provision of sales and marketing services in the United States; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. In addition, it provides clinical and commercial manufacturing, assay, formulation and process development, process validation, lot release testing, stability studies, drug product formulation, fill and finish, and regulatory support services for recombinant protein, monoclonal antibodies, and antibody drug conjugates. The company serves pharmaceutical and biotechnology companies. It has strategic partnerships with Amicus Therapeutics; ABL Bio; NBE-Therapeutics; I-Mab Biopharma; NovoCodex Biopharmaceuticals Co., Ltd.; Almirall; Antengene Corporation; and Arcus Biosciences, Inc. The company was founded in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BTHI Big Time Holdings, Inc

N/A

USD151.65B N/A N/A
DFIFF Diamond Fields Resources Inc

+0.02 (+5.26%)

USD150.57B 39.43 N/A
SEMHF Siemens Healthineers AG

N/A

USD55.08B 30.99 N/A
YACAF Yancoal Australia Ltd

N/A

USD51.96B 0.20 N/A
HENOF Henkel AG & Co. KGaA

N/A

USD46.09B 30.47 15.72
MQBKY Macquarie Group Limited

+2.39 (+2.01%)

USD42.94B 24.87 9.34
PETFF PTT Public Company Limited

N/A

USD36.37B 32.14 0.21
SZHIF Shenzhou International Group H..

N/A

USD36.08B 42.23 N/A
SUVPF Sartorius Aktiengesellschaft

N/A

USD35.39B 133.84 N/A
SARTF Sartorius Aktiengesellschaft

N/A

USD35.36B 112.25 N/A

ETFs Containing WXIBF

Symbol Name Weight Mer Price(Change) Market Cap
FXI iShares China Large-Cap E.. 0.00 % 0.74 %

+0.06 (+0.13%)

USD4.11B
IDFX:LSE iShares China Large Cap U.. 0.00 % 0.74 %

-0.15 (-0.11%)

USD0.69B

Market Performance

  Market Performance vs.
Industry/Classification ()
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.88% N/A N/A 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.88% N/A N/A 39% F
Trailing 12 Months  
Capital Gain 727.39% N/A N/A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 727.39% N/A N/A 91% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 217.90% N/A N/A 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 217.90% N/A N/A 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 340.50% N/A N/A 16% F
Risk Adjusted Return 63.99% N/A N/A 89% B+
Market Capitalization 58.87B N/A N/A 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
()
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 222.30 N/A N/A 4% F
Price/Book Ratio 18.13 N/A N/A 10% F
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA 28.82 N/A N/A 15% F
Management Effectiveness  
Return on Equity 10.02% N/A N/A 73% C
Return on Invested Capital 7.86% N/A N/A 68% D+
Return on Assets 4.03% N/A N/A 80% B-
Debt to Equity Ratio 8.94% N/A N/A 67% D+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.10 N/A N/A 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.